A West Australian family has put out a desperate plea for help to save their two-year-old daughter Aurelia who has been diagnosed with pulmonary hypertension – a rare and life-threatening ...

Interleukin-6 transcriptionally upregulated CTRP7 in pulmonary artery smooth muscle cells, linking inflammation to treatment resistance. CTRP7 emerged as a mechanistically important biomarker that ...

Please provide your email address to receive an email when new articles are posted on . Researchers used data from the GRIPHON study and open-label extension study. The median selexipag dose was 1,000 ...

Upon final approval of this ANDA by USFDA, Alembic may be eligible for 180 days of generic marketing exclusivity in the U.S. (Image Credits: Pixabay) Alembic Pharmaceuticals Limited on Monday ...

New Delhi: Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) ...

Alembic Pharmaceuticals Ltd on Monday said it has received tentative approval from the US health regulator for its generic version of Selexipag injection used in the treatment of pulmonary arterial ...

Alembic Pharmaceuticals share price rose in the early morning trade on July 15 after the company received tentative approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug ...

United Therapeutics specializes in therapies for pulmonary arterial hypertension, or high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin ...

This approval allows the company to enter the market with a generic equivalent of Uptravi® for injection, which is originally produced by Actelion Pharmaceuticals US, Inc. Notably, the manufacturing ...

Global pharma major Lupin Limited (Lupin) on Thursday announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug ...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary ...

Zydus Lifesciences subsidiary Zydus Worldwide DMCC has received final approval from the U.S. Food and Drug Administration to market Selexipag Tablets in different strengths. Indicated in adults for ...